ArticleJournal of bone oncology2026
Metal ion exposure after oncologic megaprosthesis salvage surgery: a systematic review.
Article in Journal of bone oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Megaprostheses may contain multiple modular junctions and, depending on implant design, specific coupling or hinge mechanisms that can contribute to fretting, wear, corrosion, and systemic metal ion release. This systematic review evaluated blood metal ion levels in patients undergoing limb-salvage oncologic surgery with a megaprosthesis. Material and methods: A systematic review was conducted following PRISMA guidelines. PubMed, Scopus, and Web of Science were searched from inception to September 16, 2024. Studies were eligible if they reported metal ion levels after upper or lower oncologic megaprosthesis reconstruction. Data were extracted for cobalt, chromium, titanium, aluminium, molybdenum, and silver at prespecified postoperative intervals (0-2 months, 2-12 months, and > 12 months), together with study and patient characteristics, anatomical location/reconstruction type, and reported complications. Data were summarized using arithmetic means and sample-size-weighted means. Results: Thirteen studies comprising 16 cohorts and 247 patients were included. Blood cobalt, chromium, and titanium concentrations were higher in later postoperative intervals. At >12 months, mean cobalt, chromium, and titanium concentrations were 8.2 ppb, 4.2 ppb, and 8.1 ppb, respectively; upper-quartile values reached 21.1 ppb for cobalt, 11.7 ppb for chromium, and 9.6 ppb for titanium. Silver concentrations were 8.2, 2.9, and 9.2 ppb at 0-2, 2-12, and > 12 months, respectively, whereas aluminium and molybdenum were only reported beyond 12 months, with mean values of 7.8 and 0.5 ppb. No included study consistently linked elevated ion levels with systematically assessed ARMD, pseudotumor formation, renal failure, or cardiac toxicity. Conclusion: Blood cobalt, chromium, and titanium concentrations appeared higher in later postoperative intervals after oncologic limb-salvage reconstruction with megaprostheses. Some patients may exceed commonly cited thresholds, particularly for cobalt, but the clinical significance remains uncertain because relevant outcomes were inconsistently assessed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.